Roche presented Phase 3 data indicating its selective estrogen receptor degrader (SERD) giredestrant delays tumor progression in hormone receptor‑positive breast cancer, including patients without receptor mutations. ESMO presentations and coverage showed giredestrant produced clinically meaningful progression‑free survival gains versus comparator regimens, positioning Roche to differentiate its oral SERD from competitors. Company briefings and STAT reporting also highlighted the drug’s trial designs and patient cohorts; Roche emphasized the agent’s potential to broaden oral endocrine options beyond mutation‑selected populations. The results may inform regulatory filings and commercial positioning. Clinicians and payers will evaluate tolerability, comparative efficacy versus existing endocrine standards, and the implications for sequencing with CDK4/6 inhibitors and ADCs as treatment paradigms evolve.